If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

They did not have diabetes. open image in gallery Injection pens and boxes of Novo Nordisk’s weight-loss drug Wegovy are seen in November 2023. The FDA approved a new indication for use for Wegovy ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Approval announced for injection medication aimed at treatment for adults for obesity and risk of non-fatal myocardial ...

MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...

There have been 274 hospitalisations associated with weight-loss injections - far higher than the 68 previously detailed by ...